Vera Therapeutics (VERA) Stock Price, News & Analysis

Company Overview

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for immune-mediated diseases. The company’s research is centered on therapies designed to address the underlying causes of autoimmune conditions rather than primarily managing their symptoms.

Vera’s leading product candidate is atacicept, an investigational biologic designed to inhibit two proteins involved in the survival and activity of antibody-producing immune cells, B-cell activating factor and a proliferation-inducing ligand. The company is evaluating atacicept primarily as a potential treatment for IgA nephropathy, a chronic autoimmune kidney disease, in the global Phase 3 ORIGIN clinical trial.

Vera Therapeutics is headquartered in the San Francisco Bay Area and conducts development activities and clinical studies through sites in the United States and other international markets. As a clinical-stage company, Vera does not currently have an approved commercial product; its business is focused on research, clinical development and potential regulatory approval of therapies for patients with serious immune-mediated diseases.

Key Stats

• Today's Range: $33.22 to $35.54
• 50-Day Range: $28.89 to $43.13
• 52-Week Range: $22.72 to $56.05
• Volume: 1.70 million shs
• Average Volume: 1.84 million shs
• Market Capitalization: $2.45 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $80.15
• Consensus Rating: Moderate Buy

Vera Therapeutics Stock Analysis - MarketRank™

Vera Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 356th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 11 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Vera Therapeutics has a consensus price target of $80.15, representing about 135.4% upside from its current price of $34.05.

Amount of Analyst Coverage

Vera Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vera Therapeutics are expected to grow in the coming year, from ($6.44) to ($4.53) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vera Therapeutics is -5.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vera Therapeutics is -5.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vera Therapeutics has a P/B Ratio of 4.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

32.79% of the float of Vera Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Vera Therapeutics has a short interest ratio ("days to cover") of 10.81, which indicates bearish sentiment.

Change versus previous month

Short interest in Vera Therapeutics has recently increased by 18.19%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vera Therapeutics does not currently pay a dividend.

Dividend Growth

Vera Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.23

News Sentiment

Vera Therapeutics has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Vera Therapeutics this week, compared to 5 articles on an average week.

Search Interest

Only 7 people have searched for VERA on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Vera Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vera Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,307,800.00 in company stock.

Percentage Held by Insiders

15.90% of the stock of Vera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

99.21% of the stock of Vera Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 9/14/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/15/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VERA
• CIK: 1831828
• Web: veratx.com
• Phone: 650-770-0077
• Fax: N/A
• Employees: 361
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Vera Therapeutics: $80.15
• High Price Target: $125.00
• Low Price Target: $34.00
• Potential Upside/Downside: +135.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$299.61 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -84.13%
• Return on Assets: -66.79%

Debt

• Debt-to-Equity Ratio: 0.18
• Current Ratio: 10.92
• Quick Ratio: 10.92

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.48 per share
• Price / Book: 4.02

Miscellaneous

• Outstanding Shares: 72,060,000
• Free Float: 60,605,000
• Market Cap: $2.45 billion
• Optionable: Optionable
• Beta: 0.96